The Company has more than 45 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX ANNOUNCES WARRANT EXERCISE18 January 2017
ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS11 January 2017
ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE05 January 2017
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura